Mobile

An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognit...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001162-40

An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to determine whether donepezil HCl confers cognitive benefit in patients with CADASIL who have cognitive impairment.

Critère d'inclusion

  • Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL),CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia

Liens